Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Current Drug Therapy

The role of SGLT-2 inhibitors in managing type 2 diabetes

Yumiko Tsushima, MD, M. Cecilia Lansang, MD, MPH and Vinni Makin, MBBS, MD, FACE
Cleveland Clinic Journal of Medicine January 2021, 88 (1) 47-58; DOI: https://doi.org/10.3949/ccjm.88a.20088
Yumiko Tsushima
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Cecilia Lansang
Director, Main Campus Department of Endocrinology, Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vinni Makin
Director, East Region, Department of Endocrinology Diabetes, and Metabolism, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 88 no. 1 47-58
DOI 
https://doi.org/10.3949/ccjm.88a.20088
PubMed 
33384315

Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online December 31, 2020.

Copyright & Usage 
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Yumiko Tsushima, MD
  1. Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic
  1. M. Cecilia Lansang, MD, MPH
  1. Director, Main Campus Department of Endocrinology, Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. Vinni Makin, MBBS, MD, FACE⇑
  1. Director, East Region, Department of Endocrinology Diabetes, and Metabolism, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  1. Address:
    Vinni Makin, MBBS, MD, FACE, Department of Endocrinology Diabetes, and Metabolism, F20, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; makinv{at}ccf.org

Cited By...

  • 13 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 88 (1)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The role of SGLT-2 inhibitors in managing type 2 diabetes
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The role of SGLT-2 inhibitors in managing type 2 diabetes
Yumiko Tsushima, M. Cecilia Lansang, Vinni Makin
Cleveland Clinic Journal of Medicine Jan 2021, 88 (1) 47-58; DOI: 10.3949/ccjm.88a.20088

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The role of SGLT-2 inhibitors in managing type 2 diabetes
Yumiko Tsushima, M. Cecilia Lansang, Vinni Makin
Cleveland Clinic Journal of Medicine Jan 2021, 88 (1) 47-58; DOI: 10.3949/ccjm.88a.20088
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • SODIUM-GLUCOSE COTRANSPORTER-2
    • EFFECT ON GLYCEMIC CONTROL
    • EFFECT ON CARDIOVASCULAR OUTCOMES
    • POSSIBLE MECHANISMS OF CARDIOVASCULAR BENEFIT
    • EFFECT ON RENAL OUTCOMES
    • MECHANISM OF RENAL PROTECTION
    • EFFECT ON METABOLIC OUTCOMES
    • STUDIES IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    • ADVERSE EFFECTS OF SGLT-2 INHIBITORS
    • REVIEW OF THE GUIDELINES
    • FUTURE DIRECTIONS
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • SGLT-2 inhibitors for type 2 diabetes
  • PubMed
  • Google Scholar

Cited By...

  • Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study
  • SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
  • Google Scholar

More in this TOC Section

  • Reducing the risks when using benzodiazepines to treat insomnia: A public health approach
  • Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
  • A practical guide for buprenorphine initiation in the primary care setting
Show more Current Drug Therapy

Similar Articles

Subjects

  • Cardiology
  • Diabetes
  • Drug Therapy
  • Endocrinology
  • Nephrology
  • Obesity
  • Preventive Care
  • Vascular Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire